Autopsy report · NCT05857748

Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease

“Company decision due to the transfer of ownership of the product”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Dry Eye Disease

Interventions

lifitegrast

Participants

0

Trials that died the same way

• Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations
  “company decision” (68% match in meaning)
• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (67% match in meaning)
• Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
  “Company business decision” (63% match in meaning)
• A Phase 2 Extension of Study GCS-100-CS-4003
  “Corporate decision” (61% match in meaning)
• Clinical Performance Evaluation of the Hativ P30
  “Company's internal decision.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.